S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
OTCMKTS:HCYTD

H-CYTE - HCYTD Competitors

$2.02
-1.98 (-49.50%)
(As of 07/11/2022)
Add
Compare
Today's Range
$2.02
$2.77
50-Day Range
$0.02
$4.00
52-Week Range
$2.02
$77.00
Volume
400 shs
Average Volume
103 shs
Market Capitalization
$521,160.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

HCYTD vs. RGIN, BIPHD, ACAI, VRSEF, CRRVF, HDII, USAQ, VGLS, RSPI, and ARGSQ

Should you be buying H-CYTE stock or one of its competitors? The main competitors of H-CYTE include Regenicin (RGIN), Safeplus International (BIPHD), Safeplus International (ACAI), Verisante Technology (VRSEF), CVR Medical (CRRVF), Hypertension Diagnostics (HDII), QHSLab (USAQ), VG Life Sciences (VGLS), RespireRx Pharmaceuticals (RSPI), and Argos Therapeutics (ARGSQ). These companies are all part of the "medical" sector.

H-CYTE vs.

H-CYTE (OTCMKTS:HCYTD) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Regenicin received 81 more outperform votes than H-CYTE when rated by MarketBeat users.

CompanyUnderperformOutperform
H-CYTEN/AN/A
RegenicinOutperform Votes
81
69.83%
Underperform Votes
35
30.17%

0.0% of Regenicin shares are owned by institutional investors. 5.2% of H-CYTE shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, H-CYTE's average media sentiment score of 0.00 equaled Regenicin's average media sentiment score.

Company Overall Sentiment
H-CYTE Neutral
Regenicin Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
H-CYTE
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Regenicin
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Regenicin has lower revenue, but higher earnings than H-CYTE.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
H-CYTE$1.61 million0.32-$4.80 millionN/AN/A
RegenicinN/AN/A-$670 thousandN/AN/A

H-CYTE has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Regenicin has a beta of -2.47, meaning that its share price is 347% less volatile than the S&P 500.

Regenicin has a net margin of 0.00% compared to H-CYTE's net margin of -450.40%.

Company Net Margins Return on Equity Return on Assets
H-CYTE -450.40% N/A -777.68%
Regenicin N/A N/A -12,737.23%

Summary

H-CYTE and Regenicin tied by winning 4 of the 8 factors compared between the two stocks.


Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCYTD vs. The Competition

MetricH-CYTESurgical & medical instruments IndustryMedical SectorOTCMKTS Exchange
Market Cap$521,000.00$3.37B$4.41B$6.48B
Dividend YieldN/A1.55%7.26%35.51%
P/E RatioN/A26.06123.551.85
Price / Sales0.3267.272,950.751,206.27
Price / CashN/A41.4022.8919.99
Price / Book-0.065.836.466.03
Net Income-$4.80M$85.56M$166.90M$726.41M
7 Day PerformanceN/A4.44%4.70%1.81%
1 Month PerformanceN/A11.84%10.80%6.27%
1 Year PerformanceN/A-26.20%-27.19%79.93%

H-CYTE Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGIN
Regenicin
0 of 5 stars
$0.00
flat
N/AN/A$523,000.00N/A0.003Gap Up
BIPHD
Safeplus International
0 of 5 stars
$0.07
flat
N/A-66.5%$382,000.00N/A0.00N/A
ACAI
Safeplus International
0 of 5 stars
$0.07
flat
N/A-52.8%$382,000.00N/A0.002
VRSEF
Verisante Technology
0 of 5 stars
$0.03
flat
N/AN/A$257,000.00N/A0.00N/A
CRRVF
CVR Medical
0 of 5 stars
$0.01
flat
N/AN/A$1.01MN/A-0.50N/A
HDII
Hypertension Diagnostics
0 of 5 stars
$0.01
flat
N/A-61.0%$1.15MN/A0.002,017News Coverage
Gap Up
High Trading Volume
USAQ
QHSLab
0 of 5 stars
$0.20
-4.8%
N/A-74.1%$1.76M$1.41M0.003News Coverage
Gap Up
VGLS
VG Life Sciences
0 of 5 stars
N/AN/A-93.3%$512,000.00N/A0.001High Trading Volume
RSPI
RespireRx Pharmaceuticals
0 of 5 stars
$0.00
flat
N/A-79.7%$538,000.00N/A0.002
ARGSQ
Argos Therapeutics
0 of 5 stars
$0.05
flat
N/AN/A$572,000.00$1.90M0.0021
This page (OTCMKTS:HCYTD) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.